{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:13:26Z","timestamp":1790230406756,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UG1CA189823"],"award-info":[{"award-number":["UG1CA189823"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U10CA180790"],"award-info":[{"award-number":["U10CA180790"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U10CA180833"],"award-info":[{"award-number":["U10CA180833"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U10CA180836"],"award-info":[{"award-number":["U10CA180836"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U10CA180838"],"award-info":[{"award-number":["U10CA180838"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U10CA180850"],"award-info":[{"award-number":["U10CA180850"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U10CA180857"],"award-info":[{"award-number":["U10CA180857"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","geriatriconcology.net","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.jgo.2018.03.018","type":"journal-article","created":{"date-parts":[[2018,4,17]],"date-time":"2018-04-17T05:00:05Z","timestamp":1523941205000},"page":"321-328","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611)"],"prefix":"10.1016","volume":"9","author":[{"given":"Michael","family":"Tallarico","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared C.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew","family":"Seisler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline M.","family":"Lafky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arti","family":"Hurria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aminah","family":"Jatoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey J.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyman B.","family":"Muss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce D.","family":"Cheson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sin-Ho","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Byrd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chadi","family":"Nabhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgo.2018.03.018_bb0005","series-title":"SEER cancer statistics review, 1975\u20132013","year":"2015"},{"key":"10.1016\/j.jgo.2018.03.018_bb0010","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1365-2141.2011.08934.x","article-title":"Analysis of very elderly (\u226580\u202fyears) non-hodgkin lymphoma: impact of functional status and co-morbidities on outcome","volume":"156","author":"Nabhan","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jgo.2018.03.018_bb0015","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1023\/A:1008205619617","volume":"8","year":"1997","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jgo.2018.03.018_bb0020","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1093\/annonc\/mdm563","article-title":"Non-Hodgkin's lymphoma in very elderly patients over 80\u202fyears. A descriptive analysis of clinical presentation and outcome","volume":"19","author":"Thieblemont","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jgo.2018.03.018_bb0025","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.3109\/10428194.2013.780654","article-title":"Efficacy and tolerability of reduced-dose 21-day cycle rituximab and cyclophosphamide, doxorubicin, vincristine and prednisolone therapy for elderly patients with diffuse large B-cell lymphoma","volume":"54","author":"Aoki","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jgo.2018.03.018_bb0030","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1002\/1097-0142(19880515)61:10<2057::AID-CNCR2820611021>3.0.CO;2-X","article-title":"Non-Hodgkin's malignant lymphomas in patients older than 80: 70 cases","volume":"61","author":"Hoerni","year":"1988","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.jgo.2018.03.018_bb0035","first-page":"126","article-title":"Diffuse large B-cell non-Hodgkin lymphoma in the very elderly: challenges and solutions","volume":"27","author":"Latta","year":"2013","journal-title":"Oncology"},{"key":"10.1016\/j.jgo.2018.03.018_bb0040","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1200\/JCO.1998.16.7.2352","article-title":"Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity","volume":"16","author":"Gomez","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2018.03.018_bb0045","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/hon.2900130206","article-title":"High grade non-Hodgkin's lymphoma in the elderly\u201412\u202fyear experience in the Grampian Region of Scotland","volume":"13","author":"Neilly","year":"1995","journal-title":"Hematol Oncol"},{"issue":"25","key":"10.1016\/j.jgo.2018.03.018_bb0050","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1200\/JCO.2011.34.7625","article-title":"Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study","volume":"29","author":"Hurria","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2018.03.018_bb0055","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1056\/NEJM199912303412706","article-title":"Underrepresentation of patients 65\u202fyears of age or older in cancer-treatment trials","volume":"341","author":"Hutchins","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgo.2018.03.018_bb0060","doi-asserted-by":"crossref","first-page":"4626","DOI":"10.1200\/JCO.2004.02.175","article-title":"Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration","volume":"22","author":"Talarico","year":"2004","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jgo.2018.03.018_bb0065","first-page":"18","article-title":"Greater risks of chemotherapy toxicity in elderly patients with cancer","volume":"1","author":"Repetto","year":"2003","journal-title":"J Support Oncol"},{"key":"10.1016\/j.jgo.2018.03.018_bb0070","series-title":"The elements of statistical learning: data mining, inference, and prediction","author":"Hastie","year":"2009"},{"key":"10.1016\/j.jgo.2018.03.018_bb0075","series-title":"Multiple imputation for nonresponse in surveys","author":"Rubin","year":"1987"},{"key":"10.1016\/j.jgo.2018.03.018_bb0080","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1056\/NEJM199405053301801","article-title":"Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma","volume":"330","author":"Wood","year":"1994","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jgo.2018.03.018_bb0085","article-title":"Efficacy and toxicity of adjuvant chemotherapy in elderly patients with colorectal cancer: the study","volume":"1","author":"Lund","year":"2017","journal-title":"Open"},{"issue":"3","key":"10.1016\/j.jgo.2018.03.018_bb0090","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1080\/10428194.2016.1211279","article-title":"The impacts of initial and relative dose intensity of R-CHOP on outcomes of elderly patients with diffuse large B-cell lymphoma","volume":"58","author":"Kanemasa","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jgo.2018.03.018_bb0095","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00277-007-0399-y","article-title":"Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP","volume":"87","author":"Bosly","year":"2008","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jgo.2018.03.018_bb0100","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1002\/1097-0142(19900915)66:6<1124::AID-CNCR2820660608>3.0.CO;2-T","article-title":"Survival of diffuse large cell lymphoma. A multivariate analysis including dose intensity variables","volume":"66","author":"Epelbaum","year":"1990","journal-title":"Cancer"},{"key":"10.1016\/j.jgo.2018.03.018_bb0105","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1200\/JCO.1990.8.6.963","article-title":"Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis","volume":"8","author":"Kwak","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2018.03.018_bb0110","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00277-008-0447-2","article-title":"Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy","volume":"87","author":"Pettengell","year":"2008","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jgo.2018.03.018_bb0115","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1756-9966-28-116","article-title":"Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma","volume":"28","author":"Terada","year":"2009","journal-title":"J Exp Cancer Res"},{"key":"10.1016\/j.jgo.2018.03.018_bb0120","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/07350015.1988.10509663","article-title":"Missing-data adjustments in large surveys","volume":"6","author":"Little","year":"1988","journal-title":"J Bus Econ Stat"},{"issue":"3","key":"10.1016\/j.jgo.2018.03.018_bb0125","first-page":"189","article-title":"The utility of lactate dehydrogenase in the follow up of patients with diffuse large B-cell lymphoma","volume":"35","author":"William","year":"2013","journal-title":"Rev Bras Hematol Hemoter"},{"key":"10.1016\/j.jgo.2018.03.018_bb0130","series-title":"\u201cCancer diagnosis - understanding cancer\u201d. Understanding cancer. Stanford Medicine","author":"Stanford Cancer Center","year":"1992"},{"key":"10.1016\/j.jgo.2018.03.018_bb0135","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/0002-9343(92)90200-U","article-title":"Value of functional status as a predictor of mortality: results of a prospective study","volume":"93","author":"Reuben","year":"1992","journal-title":"Am J Med"},{"key":"10.1016\/j.jgo.2018.03.018_bb0140","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jgo.2018.03.018_bb0145","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jgo.2018.03.018_bb0150","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2014-02-556399","article-title":"Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia","volume":"124","author":"Pflug","year":"2014","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jgo.2018.03.018_bb0155","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","article-title":"The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"109","author":"Sehn","year":"2007","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jgo.2018.03.018_bb0160","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1634\/theoncologist.3-3-189","article-title":"Prognostic factors in aggressive non-Hodgkin's lymphomas","volume":"3","author":"Nicolaides","year":"1998","journal-title":"Oncologist"},{"key":"10.1016\/j.jgo.2018.03.018_bb0165","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1182\/blood-2013-07-517037","article-title":"Suboptimal dosing of rituximab in male and female patients with DLBCL","volume":"123","author":"Pfreundschuh","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jgo.2018.03.018_bb0170","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1182\/blood-2013-12-543314","article-title":"Is rituximab one for all ages and each sex?","volume":"123","author":"Habermann","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jgo.2018.03.018_bb0175","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/bjh.12008","article-title":"Single-agent lenalidomide in relapsed\/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences","volume":"159","author":"Eve","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jgo.2018.03.018_bb0180","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1200\/JCO.2003.08.010","article-title":"Participation of patients 65\u202fyears of age or older in cancer clinical trials","volume":"21","author":"Lewis","year":"2003","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jgo.2018.03.018_bb0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0033559","article-title":"Underrepresentation of elderly people in randomised controlled trials. The example of trials of 4 widely prescribed drugs","volume":"7","author":"Konrat","year":"2012","journal-title":"Plos One"}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406818301310?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406818301310?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T02:27:56Z","timestamp":1720232876000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879406818301310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S1879406818301310"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2018.03.018","relation":{},"ISSN":["1879-4068"],"issn-type":[{"value":"1879-4068","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611)","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2018.03.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}